FIELD: medicine.
SUBSTANCE: invention represents a drug preparation for Parkinson disease containing micronised L-DOPA (3-hydroxy-L-tyrosine) as an active ingredient, which represent stable particles containing poly(lactic-co-glycolic acid 50/50 (PLGA 50/50), or poly(lactic-co-glycolic acid 75/25 (PLGA 75/25), or poly(lactic-co-glycolic acid 50/50 with carboxyl group (PLGA-COOH 50/50), or lactic acid polymer (PLA) in an amount of 75.0÷79.0 wt %, D-mannitol in an amount of 7.5÷8.0 wt %, as well as either polyvinyl alcohol (PVA) or Tween 80.
EFFECT: treating Parkinson disease more effectively.
2 cl, 4 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITION FOR TREATING PARKINSON'S DISEASE | 2017 |
|
RU2697411C2 |
| METHOD OF CORRECTION OF OXIDATIVE STATUS IN PARKINSON'S DISEASE IN EXPERIMENT | 2023 |
|
RU2800859C1 |
| AGENT FOR TREATMENT AND PREVENTION OF PARKINSON'S DISEASE | 2006 |
|
RU2324492C1 |
| PARKINSON'S DISEASE TREATMENT MODE | 2007 |
|
RU2353382C1 |
| COMBINATION OF RILUSOL AND L-DOFA FOR TREATING PARKINSON'S DISEASE | 1999 |
|
RU2225204C2 |
| PHARMACEUTICAL COMPOSITIONS FOR TREATING PARKINSON'S DISEASE | 2009 |
|
RU2540470C9 |
| MEDICATION FOR TREATING PARKINSON'S DISEASE | 2009 |
|
RU2418577C1 |
| ORGANIC COMPOUNDS | 2015 |
|
RU2785871C2 |
| PEPTIDE WITH NEUROPROTECTIVE ACTIVITY ON MODEL OF MFTP-INDUCED PARKINSONISM AND A PHARMACEUTICAL COMPOSITION ON ITS BASIS | 2017 |
|
RU2662429C1 |
| PHARMACEUTICAL COMPOSITION FOR RECOVERY FUNCTION OF SYMPATHETIC-ADRENAL SYSTEM, METHOD OF EVALUATION OF INDIVIDUAL EFFECTIVENESS OF THIS COMPOSITION FOR PATIENT THERAPY | 1999 |
|
RU2157196C1 |
